ACAD

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Headquartered in San Diego, California, the company was founded in 1993 and employs approximately 650 people. ACADIA's flagship product is NUPLAZID (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, which generates the majority of the company's revenue. The company markets NUPLAZID in the United States through its own commercial infrastructure and has partnerships for international markets. ACADIA's pipeline includes trofinetide, approved as DAYBUE in 2023 for Rett syndrome, representing the first FDA-approved treatment for this rare genetic neurological disorder. The company acquired the rights to trofinetide through its March 2023 acquisition of Neuren Pharmaceuticals' U.S. commercialization rights. ACADIA focuses on rare disease neurology and has additional development programs exploring pimavanserin for other neuropsychiatric conditions. The company reported total revenues of approximately $573 million in 2022, driven primarily by NUPLAZID sales. ACADIA maintains research and development facilities in San Diego and operates as a fully integrated biopharmaceutical company with capabilities spanning drug discovery, clinical development, regulatory affairs, and commercial operations in the specialized neuroscience market.